Paul Peter Tak, Chief Executive Officer at Candel Therapeutics, Inc. (CADL), sold 280,245 shares at $11.50 ($3.2M) on 2026-09-10, disclosed to the SEC on 2026-09-11.
Scheduled sale ($3.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.50 | 220,866 | $2.5M | 80.4% |
| 2 | $10.46 | 59,379 | $621K | 19.6% |
| Total | $11.28 avg | 280,245 | $3.2M | 100% |
| Filing → |
| CADL | SELL | 2025-01-10 | $348K | — | Filing → |
| CADL | SELL | 2024-12-03 | $445K | — | Filing → |
| CADL | SELL | 2024-07-19 | $292K | — | Filing → |